{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:51Z","timestamp":1786986891959,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cllc.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T21:53:32Z","timestamp":1749160412000},"page":"e503-e513.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non\u2013Small-Cell Lung Cancer According to ALK Fusion and Mutation Status"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-4359","authenticated-orcid":false,"given":"Lyudmila","family":"Bazhenova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf M.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingkuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.cllc.2025.05.016_bib0001","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2025.05.016_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00595-017-1497-7","article-title":"Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy","volume":"48","author":"Saito","year":"2018","journal-title":"Surg Today"},{"issue":"7153","key":"10.1016\/j.cllc.2025.05.016_bib0003","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.cllc.2025.05.016_bib0004","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2025.05.016_bib0005","series-title":"Alunbrig [package insert]","year":"2022"},{"issue":"10","key":"10.1016\/j.cllc.2025.05.016_bib0006","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.cllc.2025.05.016_bib0007","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cllc.2025.05.016_bib0008","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.05.016_bib0009","article-title":"Long-term efficacy and safety of brigatinib in crizotinib-refractory ALK+ non\u2013small cell lung cancer: final results of the phase 1\/2 and randomized phase 2 (ALTA) trials","volume":"3","author":"Gettinger","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"22","key":"10.1016\/j.cllc.2025.05.016_bib0010","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.05.016_bib0011","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial","volume":"15","author":"Huber","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.05.016_bib0012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/cancers9090118","article-title":"EML4-ALK variants: biological and molecular properties, and the implications for patients","volume":"9","author":"Sabir","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"28","key":"10.1016\/j.cllc.2025.05.016_bib0013","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.05.016_bib0014","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.05.016_bib0015","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.05.016_bib0016","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.05.016_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.05.016_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2025.05.016_bib0019","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.05.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100333","article-title":"Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer","volume":"7","author":"Wolf","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2025.05.016_bib0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2025.05.016_bib0022","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1878-0261.13446","article-title":"EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries","volume":"17","author":"Elshatlawy","year":"2023","journal-title":"Mol Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.05.016_bib0023","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.05.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100337","article-title":"Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients","volume":"7","author":"Hua","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.cllc.2025.05.016_bib0025","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.cllc.2025.05.016_bib0026","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.jtho.2019.06.028","article-title":"A compound L1196M\/G1202R ALK mutation in a patient with ALK-positive lung cancer with acquired resistance to brigatinib also confers primary resistance to lorlatinib","volume":"14","author":"Sharma","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.cllc.2025.05.016_bib0027","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cllc.2025.05.016_bib0028","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2025.05.016_bib0029","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer v5.2024. 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed: May 3, 2024."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:02:23Z","timestamp":1778943743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425001287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525730425001287"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.05.016","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non\u2013Small-Cell Lung Cancer According to ALK Fusion and Mutation Status","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Development Center Americas, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}